Dermata Therapeutics Inc.

0.91
-0.02 (-2.38%)
At close: Apr 04, 2025, 10:16 AM

Dermata Therapeutics Statistics

Share Statistics

Dermata Therapeutics has 5.43M shares outstanding. The number of shares has increased by 1122.96% in one year.

Shares Outstanding 5.43M
Shares Change (YoY) 1122.96%
Shares Change (QoQ) 166.11%
Owned by Institutions (%) 38.16%
Shares Floating 3.99M
Failed to Deliver (FTD) Shares 738
FTD / Avg. Volume 0.04%

Short Selling Information

The latest short interest is 93.74K, so 4.59% of the outstanding shares have been sold short.

Short Interest 93.74K
Short % of Shares Out 4.59%
Short % of Float 10.63%
Short Ratio (days to cover) 0.52

Valuation Ratios

The PE ratio is 0 and the forward PE ratio is -0.32. Dermata Therapeutics's PEG ratio is 0.

PE Ratio 0
Forward PE -0.32
PS Ratio 0
Forward PS 0.3
PB Ratio 0
P/FCF Ratio 0
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Dermata Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1602.58, with a Debt / Equity ratio of 0.

Current Ratio 1602.58
Quick Ratio 1602.58
Debt / Equity 0
Debt / EBITDA 0
Debt / FCF 0
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.54B
Employee Count 8
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -84.54% in the last 52 weeks. The beta is 0.58, so Dermata Therapeutics's price volatility has been higher than the market average.

Beta 0.58
52-Week Price Change -84.54%
50-Day Moving Average 1.19
200-Day Moving Average 1.55
Relative Strength Index (RSI) 33.17
Average Volume (20 Days) 1.66M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -12.51B
Net Income -12.29B
EBITDA -12.51B
EBIT n/a
Earnings Per Share (EPS) -8032.22
Full Income Statement

Balance Sheet

The company has 3.16M in cash and 0 in debt, giving a net cash position of 3.16M.

Cash & Cash Equivalents 3.16M
Total Debt 0
Net Cash 3.16M
Retained Earnings -65.68B
Total Assets 3.53M
Working Capital 1.56M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -11.16B and capital expenditures 0, giving a free cash flow of -11.16B.

Operating Cash Flow -11.16B
Capital Expenditures 0
Free Cash Flow -11.16B
FCF Per Share -7297.13
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for DRMA is $6, which is 525% higher than the current price. The consensus rating is "Buy".

Price Target $6
Price Target Difference 525%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on May 16, 2024. It was a backward split with a ratio of 1:15.

Last Split Date May 16, 2024
Split Type backward
Split Ratio 1:15

Scores

Altman Z-Score -35.52
Piotroski F-Score 2